21 related articles for article (PubMed ID: 38588519)
1. Risk of acquiring extended-spectrum β-lactamase-producing Klebsiella species and Escherichia coli from prior room occupants in the intensive care unit.
Ajao AO; Johnson JK; Harris AD; Zhan M; McGregor JC; Thom KA; Furuno JP
Infect Control Hosp Epidemiol; 2013 May; 34(5):453-8. PubMed ID: 23571360
[TBL] [Abstract][Full Text] [Related]
2. The effect of a hospital-wide urine culture screening intervention on the incidence of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species.
Han JH; Bilker WB; Nachamkin I; Zaoutis TE; Coffin SE; Linkin DR; Hu B; Tolomeo P; Fishman NO; Lautenbach E
Infect Control Hosp Epidemiol; 2013 Nov; 34(11):1160-6. PubMed ID: 24113599
[TBL] [Abstract][Full Text] [Related]
3. Urinary tract infections in older adults: associated factors for extended-spectrum beta-lactamase production.
Alkan S; Balkan II; Surme S; Bayramlar OF; Kaya SY; Karaali R; Mete B; Aygun G; Tabak F; Saltoglu N
Front Microbiol; 2024; 15():1384392. PubMed ID: 38784804
[TBL] [Abstract][Full Text] [Related]
4. Spatiotemporal distribution of community-acquired phenotypic extended-spectrum beta-lactamase
Smith MW; Carrel M; Shi Q; Hasegawa S; Clore G; Tang Z; Perencevich E; Goto M
Infect Control Hosp Epidemiol; 2024 Apr; 45(4):540-542. PubMed ID: 38073591
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bacteremic pneumonia caused by
Li F; Zhu J; Zheng Y; Fang Y; Hu L; Xiong J
Saudi Med J; 2024 Mar; 45(3):241-251. PubMed ID: 38438206
[TBL] [Abstract][Full Text] [Related]
6. Machine-learning-based risk assessment tool to rule out empirical use of ESBL-targeted therapy in endemic areas.
Ravkin HD; Ravkin RM; Rubin E; Nesher L
J Hosp Infect; 2024 Apr; 149():90-97. PubMed ID: 38679390
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of bloodstream infections caused by extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae in Switzerland, 2015-2022: secular trends and association with the COVID-19 pandemic.
Damonti L; Gasser M; Kronenberg A; Buetti N
J Hosp Infect; 2024 Jun; ():. PubMed ID: 38838742
[TBL] [Abstract][Full Text] [Related]
8. Surveillance and Resistance of Community-Onset Extended-Spectrum β-Lactamase-Producing
He C; Wu S; Wang X; Li L; Yan Z
Surg Infect (Larchmt); 2024 Apr; 25(3):247-252. PubMed ID: 38588519
[No Abstract] [Full Text] [Related]
9. Community carriage of ESBL-producing
Raffelsberger N; Buczek DJ; Svendsen K; Småbrekke L; Pöntinen AK; Löhr IH; Andreassen LLE; Simonsen GS; ; Sundsfjord A; Gravningen K; Samuelsen Ø
mSphere; 2023 Aug; 8(4):e0002523. PubMed ID: 37306968
[TBL] [Abstract][Full Text] [Related]
10. Infections caused by extended-spectrum β-lactamase-producing Enterobacterales after rectal colonization with ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Denkel LA; Maechler F; Schwab F; Kola A; Weber A; Gastmeier P; Pfäfflin F; Weber S; Werner G; Pfeifer Y; Pietsch M; Leistner R
Clin Microbiol Infect; 2020 Aug; 26(8):1046-1051. PubMed ID: 31809805
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
13. Increasing Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States.
Thaden JT; Fowler VG; Sexton DJ; Anderson DJ
Infect Control Hosp Epidemiol; 2016 Jan; 37(1):49-54. PubMed ID: 26458226
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
